Tuesday, October 20-Thursday, October 22
World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
The ENDURANCE trial was just published in @NEJM hot off the press: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157
@VincentRK joined #HealthcareUnfiltered EXPRESS to explain the importance of this trial and why it mattered. Check it out right here.
@myelomaMD @Rfonsi1 @SagarLonialMD
ALERT: Major MM therapy paradigm shift with ENDURANCE trial showing less therapy as good as indefinite therapy. On behalf of patients and clinicians, thank you for doing this study.
Learn more about our active myeloma trials (incl. for patients with smoldering myeloma, newly diagnosed myeloma, & myeloma w/ kidney failure) on our website:
#FindingsFriday: New in @NEJM, results from E1A11/ENDURANCE show no survival benefit—but more toxicity—w/ indefinite lenalidomide maintenance vs. a fixed 2-year duration in newly diagnosed #MultipleMyeloma. View the full publication: https://bit.ly/3QZOU1I #Myeloma #HemOnc
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
32
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
